• A groundbreaking clinical trial demonstrates that AI-guided cardiac ablation combined with pulmonary vein isolation achieves 88% success rate in treating persistent atrial fibrillation, compared to 70% with standard treatment alone.
• The TAILORED-AF trial, involving 370 patients across 26 centers in 5 countries, shows particular benefits for patients with longer AF duration, marking a significant advancement in personalized cardiac treatment.
• The AI-guided approach, while requiring longer procedure times, maintained similar safety profiles to standard treatment and represents the first successful application of artificial intelligence in directing cardiac intervention.